Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Event-Driven

HD Hyundai Heavy Industries  / Event-Driven

The Korea Exchange (KRX) will announce the results of the December 2021 review of the <a href="https://www.smartkarma.com/entities/korea-stock-exchange-kospi-200-index" target="_blank" data-smartkarma-citation="entities:26021:1" rel="noopener">Korea Stock Exchange Kospi 200 Index (KOSPI2 INDEX)</a> later this month and the constituent changes will be effective after the close of trading on 9 December.With the review period now complete, we see 7 potential inclusions (5 regular + 2 Fast Entry) and 8 potential deletions from the index. There is one extra deletion to keep the number of index constituents at 200 following the inclusion of SK Square in the index post its spin-off from <a href="https://www.smartkarma.com/entities/sk-telecom-co-ltd-bbccd86c-474d-4a4d-946d-10e911a225a2" target="_blank" data-smartkarma-citation="entities:395:1" rel="noopener">SK Telecom (017670 KS)</a>.The potential regular inclusions are <a href="https://www.smartkarma.com/entities/f-f-co-ltd-new" target="_blank" data-smartkarma-citation="entities:33479:1" rel="noopener">F&amp;F (383220 KS)</a>, <a href="https://www.smartkarma.com/entities/skckolonpi-inc" target="_blank" data-smartkarma-citation="entities:9196:1" rel="noopener">Skckolonpi Inc (178920 KS)</a>, <a href="https://www.smartkarma.com/entities/meritz-financial-group-inc" target="_blank" data-smartkarma-citation="entities:11776:1" rel="noopener">Meritz Financial Group (138040 KS)</a>, <a href="https://www.smartkarma.com/entities/sl-corp" target="_blank" data-smartkarma-citation="entities:20694:1" rel="noopener">SL Corp (005850 KS)</a> and <a href="https://www.smartkarma.com/entities/myoung-shin-industrial-co-ltd" target="_blank" data-smartkarma-citation="entities:29698:1" rel="noopener">Myoung Shin Industrial Co.,Ltd (009900 KS)</a> while the potential Fast Entry inclusions are <a href="https://www.smartkarma.com/entities/hyundai-heavy-industries-co-ltd" target="_blank" data-smartkarma-citation="entities:33808:1" rel="noopener">Hyundai Heavy Industries (329180 KS)</a> and <a href="https://www.smartkarma.com/entities/kakao-pay-corp" target="_blank" data-smartkarma-citation="entities:29675:1" rel="noopener">Kakao Pay (377300 KS)</a>.The potential deletions are <a href="https://www.smartkarma.com/entities/samyang-foods-co-ltd" target="_blank" data-smartkarma-citation="entities:9100:1" rel="noopener">Samyang Foods (003230 KS)</a>, <a href="https://www.smartkarma.com/entities/ilyang-pharmaceutical-co-ltd" target="_blank" data-smartkarma-citation="entities:2789:1" rel="noopener">Ilyang Pharmaceutical Co., (007570 KS)</a>, <a href="https://www.smartkarma.com/entities/lx-holdings" target="_blank" data-smartkarma-citation="entities:33384:1" rel="noopener">LX Holdings (383800 KS)</a>, <a href="https://www.smartkarma.com/entities/lotte-himart-co-ltd" target="_blank" data-smartkarma-citation="entities:12895:1" rel="noopener">Lotte Himart (071840 KS)</a>, <a href="https://www.smartkarma.com/entities/f-f-co-ltd" target="_blank" data-smartkarma-citation="entities:15983:1" rel="noopener">F&amp;F Co Ltd (007700 KS)</a>, <a href="https://www.smartkarma.com/entities/dongwon-f-b-co-ltd" target="_blank" data-smartkarma-citation="entities:3274:1" rel="noopener">Dongwon F&amp;B (049770 KS)</a>, <a href="https://www.smartkarma.com/entities/lx-hausys-ltd" target="_blank" data-smartkarma-citation="entities:11613:1" rel="noopener">LX Hausys Ltd (108670 KS)</a> and <a href="https://www.smartkarma.com/entities/nexen-tire-corp" target="_blank" data-smartkarma-citation="entities:14206:1" rel="noopener">Nexen Tire Corp (002350 KS)</a>.There are quite a few stocks that are close adds but just miss out on making the 85% cumulative market cap cut or the 90% of current stocks from the sector in the index cut.The potential inclusions have outperformed the potential deletions since August. After giving up some gains and then consolidating, the potential inclusion have started to outperform the potential deletions again over the last week.

The Korea Exchange (KRX) will announce the results of the December 2021 review of the Korea Stock Exchange Kospi 200 Index (KOSPI2 INDEX) later this month and the constituent changes will be effective after the close of trading on 9 December.With the review period now complete, we see 7 potential inclusions (5 regular + 2 Fast Entry) and 8 potential deletions from the index. There is one extra deletion to keep the number of index constituents at 200 following the inclusion of SK Square in the index post its spin-off from SK Telecom (017670 KS).The potential regular inclusions are F&amp;F (383220 KS), Skckolonpi Inc (178920 KS), Meritz Financial Group (138040 KS), SL Corp (005850 KS) and Myoung Shin Industrial Co.,Ltd (009900 KS) while the potential Fast Entry inclusions are Hyundai Heavy Industries (329180 KS) and Kakao Pay (377300 KS).The potential deletions are Samyang Foods (003230 KS), Ilyang Pharmaceutical Co., (007570 KS), LX Holdings (383800 KS), Lotte Himart (071840 KS), F&amp;F Co Ltd (007700 KS), Dongwon F&amp;B (049770 KS), LX Hausys Ltd (108670 KS) and Nexen Tire Corp (002350 KS).There are quite a few stocks that are close adds but just miss out on making the 85% cumulative market cap cut or the 90% of current stocks from the sector in the index cut.The potential inclusions have outperformed the potential deletions since August. After giving up some gains and then consolidating, the potential inclusion have started to outperform the potential deletions again over the last week.

KOSPI200 Index Rebalance Preview:  Review Period Complete & Trades Performing Well

Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Korea/Asia, Events, IPOs

Cross Asset Strategy

The world will never be the same after COVID-19. We provided an extensive analysis of the on-going developments of COVID-19 in March. This novel coronavirus is a once in a century type of pandemic. As of 31 March, there were more than 0.79 million cases and nearly 38k deaths globally caused by COVID-19. Nearly one-quarter of the world's population is in various types of lockdowns.Our model portfolio was down 3.4% on a net basis in March 2020 (cash was 70% of our model portfolio), outperforming KOSPI which was down 11.4% in the same period. Among the 31 reports we have written so far in March, the three most widely read insights were all related to COVID-19:<ul>
<li>
<a href="https://www.smartkarma.com/insights/active-vs-passive-investing-post-covid-19-coronavirus-world" target="_blank" data-smartkarma-citation="insights:37765" rel="noopener">Active Vs. Passive Investing Post COVID-19 Coronavirus World</a> </li>
<li>
<a href="https://www.smartkarma.com/insights/why-is-the-death-rate-of-covid-19-nearly-6x-higher-in-the-u-s-than-in-south-korea" target="_blank" data-smartkarma-citation="insights:37272" rel="noopener">Why Is the Death Rate of COVID-19 Nearly 6x Higher in the U.S. Than in South Korea?</a> </li>
<li>
<a href="https://www.smartkarma.com/insights/some-encouraging-covid-19-data-from-south-korea" target="_blank" data-smartkarma-citation="insights:37340" rel="noopener">Some Encouraging COVID-19 Data from South Korea</a> </li>
</ul>

The world will never be the same after COVID-19. We provided an extensive analysis of the on-going developments of COVID-19 in March. This novel coronavirus is a once in a century type of pandemic. As of 31 March, there were more than 0.79 million cases and nearly 38k deaths globally caused by COVID-19. Nearly one-quarter of the world's population is in various types of lockdowns.Our model portfolio was down 3.4% on a net basis in March 2020 (cash was 70% of our model portfolio), outperforming KOSPI which was down 11.4% in the same period.   Among the 31 reports we have written so far in March, the three most widely read insights were all related to COVID-19:

Active Vs. Passive Investing Post COVID-19 Coronavirus World 

Why Is the Death Rate of COVID-19 Nearly 6x Higher in the U.S. Than in South Korea? 

Some Encouraging COVID-19 Data from South Korea 


Korea Stock Market Monthly Recap #46 (March 2020)

Frontier and emerging markets (Vietnam)

Dylan Waller

Nomadic Equity

Thematic (Sector/Industry)

Introduction to MedisetterI had the pleasure of interviewing Anirban Lahiri of Medisetter to discuss some of the opportunities present in Asia's healthcare industry. Medisetter is an international online medical travel search and bookings platform offering a one-stop-shop medical travel booking and planning service. Prospective patients can search and compare hospitals and clinics across different countries, receive price quotes, book appointments and also book accommodation, translators and…

Introduction to MedisetterI had the pleasure of interviewing Anirban Lahiri of Medisetter to discuss some of the opportunities present in Asia's healthcare industry. Medisetter is an international online medical travel search and bookings platform offering a one-stop-shop medical travel booking and planning service. Prospective patients can search and compare hospitals and clinics across different countries, receive price quotes, book appointments and also book accommodation, translators and…

MediSetter Interview: Insight on Opportunities in Asia's Healthcare Industry

Korea / Special Sits, Pairs, Index Rebalancing, Clepsydra Capital

Sanghyun Park

Korea / Special Sits, Pairs, Index Rebalancing

Equity Capital Markets

SillaJen Biotherapeutics (established in 2006) submitted the IPO report. The company develops potent multi-functional immunotherapeutics for cancer. In other words, it makes a virus ("Pexa-Vec") that only kills cancer cells. It is currently doing a global Phase 3 clinical trial in over 15 countries for patients with HCC. SillaJen reached an agreement with the U.S. FDA and now holds a special protocol assessment relating this Phase 3 trial. SillaJen's "Pexa-Vec" is the first engineered oncolytic virus with demonstrated intravenous delivery to tumors and induction of cancer targeting antibodies (thereby leading to improved survival rate).SillaJen has virtually no revenue at this point. Nonetheless, SillaJen was qualified for the fast-track IPO program exclusive for biotech companies. SillaJan actually passed the technology evaluation (conducted by the KRX) in May, which is required for a biotech company who wants to go public through the fast-track IPO program. In this evaluation, SillaJen got AA grade, just one notch lower than the highest grade of AAA. SillaJen is currently Korea's biggest over-the-counter company. SillaJen's Pexa-Vec was proved to be highly effective after being administered to 35 late-stage liver cancer patients in Phase 2 trial. As a result, there are high expectations that Pexa-Vec will successfully pass Phase 3 trial for commercialization.In particular, SillaJen already partnered with some of the global big players such as Transgene (Europe) and Lee's Pharmaceuticals (Hong Kong) for marketing and distribution. This is a rare case for a biotech start-up like SillaJen. SillaJen plans to complete Phase 3 trial by October 2019. The global market size of anticancer virus treatment is estimated at ₩1tril. More importantly, Pexa-Vec's real competitor in the liver cancer treatment market segment is only German drug maker Bayer's "Nexavar". Of course, SillaJen's value at this point still depends on several unknown future factors. But what seems certain at this point is that SillaJen's anticancer virus treatment drug itself is a proven product and unlikely to fail.* In Part 1 (as below), I summarized the overview of this IPO with the financials and valuation. In Part 2, I will analyze the company's growth potential and appropriate valuation level.

SillaJen Biotherapeutics (established in 2006) submitted the IPO report. The company develops potent multi-functional immunotherapeutics for cancer. In other words, it makes a virus ("Pexa-Vec") that only kills cancer cells. It is currently doing a global Phase 3 clinical trial in over 15 countries for patients with HCC. SillaJen reached an agreement with the U.S. FDA and now holds a special protocol assessment relating this Phase 3 trial. SillaJen's "Pexa-Vec" is the first engineered oncolytic virus with demonstrated intravenous delivery to tumors and induction of cancer targeting antibodies (thereby leading to improved survival rate).SillaJen has virtually no revenue at this point. Nonetheless, SillaJen was qualified for the fast-track IPO program exclusive for biotech companies. SillaJan actually passed the technology evaluation (conducted by the KRX) in May, which is required for a biotech company who wants to go public through the fast-track IPO program. In this evaluation, SillaJen got AA grade, just one notch lower than the highest grade of AAA. SillaJen is currently Korea's biggest over-the-counter company. SillaJen's Pexa-Vec was proved to be highly effective after being administered to 35 late-stage liver cancer patients in Phase 2 trial. As a result, there are high expectations that Pexa-Vec will successfully pass Phase 3 trial for commercialization.In particular, SillaJen already partnered with some of the global big players such as Transgene (Europe) and Lee's Pharmaceuticals (Hong Kong) for marketing and distribution. This is a rare case for a biotech start-up like SillaJen. SillaJen plans to complete Phase 3 trial by October 2019. The global market size of anticancer virus treatment is estimated at ₩1tril. More importantly, Pexa-Vec's real competitor in the liver cancer treatment market segment is only German drug maker Bayer's "Nexavar". Of course, SillaJen's value at this point still depends on several unknown future factors. But what seems certain at this point is that SillaJen's anticancer virus treatment drug itself is a proven product and unlikely to fail.* In Part 1 (as below), I summarized the overview of this IPO with the financials and valuation. In Part 2, I will analyze the company's growth potential and appropriate valuation level.

SillaJen IPO Part 1 - Schedule, Financials & Valuation

SillaJen Biotherapeutics (established in 2006) is indeed a rare breed in Korean pharmaceutical world. It is not a generic drug maker. It is not a biosimilar maker either. It makes new biomedical products. A majority of Korea's pharmaceutical makers are still generic drug makers. The likes of Celltrion and Samsung Bioepis have emerged as a biosimilar maker. But they are still a few. Biomedical makers are even rarer. Hanmi Pharmaceutical is one of these rare breeds. Now, another biomedical maker…

SillaJen Biotherapeutics (established in 2006) is indeed a rare breed in Korean pharmaceutical world. It is not a generic drug maker. It is not a biosimilar maker either. It makes new biomedical products. A majority of Korea's pharmaceutical makers are still generic drug makers. The likes of Celltrion and Samsung Bioepis have emerged as a biosimilar maker. But they are still a few. Biomedical makers are even rarer. Hanmi Pharmaceutical is one of these rare breeds. Now, another biomedical maker…

SillaJen's December IPO: Valuation, Growth Expectation and IPO Timing

South Korea

Bukwang Pharmaceutical Co., Ltd. produces oral hygienic, and pharmaceutical products.  The Company's products include over-the-counter drugs, toothpastes, and toothbrushes.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Bukwang Pharmaceutical (003000 KS)

KOSPI200 Index Rebalance Preview: Review Period Complete & Trades Performing Well

The review period for the KOSPI200 Dec rebalance is complete and we see 6 potential adds and 8 potential deletes. Most are high probability changes...

Brian Freitas

Korea Stock Market Monthly Recap #46 (March 2020)

The world will never be the same after COVID-19. We provided an extensive analysis of the on-going developments of COVID-19 in March. This novel...

Douglas Kim

MediSetter Interview: Insight on Opportunities in Asia's Healthcare Industry

Introduction to MedisetterI had the pleasure of interviewing Anirban Lahiri of Medisetter to discuss some of the opportunities present in Asia's...

Nomadic Equity

SillaJen IPO Part 1 - Schedule, Financials & Valuation

SillaJen Biotherapeutics (established in 2006) submitted the IPO report. The company develops potent multi-functional immunotherapeutics for...

Sanghyun Park

SillaJen's December IPO: Valuation, Growth Expectation and IPO Timing

SillaJen Biotherapeutics (established in 2006) is indeed a rare breed in Korean pharmaceutical world. It is not a generic drug maker. It is not a...

Sanghyun Park

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)